Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Saccharomyces boulardii in non-constipated IBS
NCT07168434Phase 3Recruiting
- Sponsor
- Biocodex
- Start
- Oct 2025
- Primary completion
- Oct 2026
- Modality
- Microbiome Therapeutics
- Countries
- 2
01
Overview
A Phase 3 trial of saccharomyces boulardii in irritable bowel syndrome (IBS), sponsored by Biocodex. Started Oct 2025; status: recruiting.
02
Drugs
saccharomyces boulardii
03
Conditions
irritable bowel syndrome (IBS)
Beyond the preview
Go deeper on NCT07168434.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07168434.